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We conclude that pHTh during apnoea in anaes- 
thetized humans is a good parameter to estimate real 
pH and to decide on termination of the apnoeic 
period due to acidosis. 
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Dear Editor 
Air filtration units 
Warburton et al. (1) have completed a very impor- 
tant study which has demonstrated that yet another 
product being marketed for house mite avoidance, 
has no demonstrable value on aeroallergen levels or 
indeed on symptoms of asthma. Such studies are of 
immense importance in providing objective infor- 
mation on which recommendations can be made to 
patients. At present, far too many house dust mite 
sensitive asthma sufferers are persuaded to buy 
domestic products purporting to reduce aeroallergen 
levels, and the medical profession are unable to 
provide clear cut information on their value or lack 
of it (2). 
In their discussion, Warburton et al. (1) have cast 
some doubt on our low volume personal air sampling 
technique for measuring domestic aeroallergen expo- 
sure. We would accept that there is currently no gold 
standard of actual aeroallergen exposure measure- 
ment. However, we do believe that our technique is 
of significant and proven value. The reason why 
Warburton and colleagues’ air sampling technique 
was unable to show any allergen in two-thirds of the 
samples collected was because they used very high 
volume sampling. This has the effect of cleaning the 
air with the very small quantities of allergen in the air 
being diluted by the vast volume of air sampled. Low 
volume sampling collects the allergen at a rate below 
which it is being generated, and there is infinitely less 
dilution. Furthermore, it is essential to use sonication 
to extract the allergen from the samples. Far from 
this having the effect of not reflecting airborne levels 
as suggested in the discussion of Warburton et al., it 
is far more likely to yield meaningful results, and has 
been validated in relation to sensitization (3). 
Obviously a great deal more work is required to 
optimize sampling techniques, but it would have been 
sensible for Warburton et al. to read our previous 
work in this area which has shown that high volume 
sampling is of limited or no value. 
Notwithstanding these comments, studies of aller- 
gen avoidance techniques are essential if we are to 
make meaningful progress on behalf of the very large 
number of allergic subjects who are desperately 
awaiting advice which might have therapeutic benefit. 
J. 0. WARNER AND J. A. WARNER 
Faculty of Medicine 
Southampton General Hospital 
Southampton, U.K. 
21 November 1994 
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Dear Editor 
Carbon dioxide laser bronchoscopy 
We were interested to read the report by Waller 
et al. (1) of their experiences of using laser broncho- 
scopy in the palliative treatment of 142 patients with 
tracheobronchial tumours. They achieved improve- 
ment in symptoms (predominantly dyspnoea, cough, 
stridor, and haemoptysis) in the great majority of 
their patients, with an acceptable risk of compli- 
cations, using a median of two procedures per patient 
(range l-11) requiring a median of 2 days of post- 
operative inpatient care (range 144) during a mean 
follow-up of 18.3 months. 
The majority of their patients had already been 
treated with external beam radiotherapy (XRT), but 
there is a need to compare endobronchial treatment 
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vs. XRT as primary treatments in the management of 
endotracheal or endobronchial obstruction by lung 
cancer. A number of endobronchial techniques are 
now available, including laser vaporization (now 
more usually undertaken with Nd YAG laser for the 
reasons given by the authors), brachytherapy, and 
cryotherapy. XRT has the advantages that it is easy 
to apply, requires no anaesthetic, and can be used to 
treat a comparatively large tumour volume, so that 
its beneficial effects are likely to last longer than those 
of more localized treatments. Its main disadvantages 
are that it may cause temporary oesophagitis and 
cannot be used repeatedly. Brachytherapy can be 
used repeatedly, and its effects might be expected to 
last longer than those of laser therapy because clear- 
ance with laser is confined to within the tracheal or 
bronchial lumen. It can be delivered under local 
anaesthetic, but requires the availability of a 
radiation-protected theatre. Laser can be used 
repeatedly, but usually requires general anaesthetic. 
Cryotherapy requires general anaesthetic and not 
infrequently has to be given in two or three 
applications. 
The advantages and disadvantages of these tech- 
niques in comparison with those of XRT can only 
be reliably assessed in a randomized trial. Such a trial 
is now being conducted by the Medical Research 
Council Lung Cancer Working Party (protocol 
LU18). We would therefore urge clinicians with these 
treatments available, either locally or through refer- 
ral, to consider collaborating in this trial. Protocols 
and other information can be obtained from the 
MRC Cancer Trials Office. 
D. J. GIRLING AND K. MOGHISSI 
MRC Cancer Trials OfJe 
5 Shaftesbury Road, Cambridge 
and 
Goole and District Hospital 
North Humberside, U.K. 
28 November 1994 
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Dear Editor 
Smoking should be banned on health premises 
in the U.K. 
The link between tobacco smoking and ill-health is 
well recognized. However, the Health Authorities 
and Trusts, the health ‘guardians’ of the nation, are 
unable or unwilling to stop smoking completely on 
their premises. This attitude should change. Smoking 
should be banned on all health premises in the U.K. 
It is surprising and ironic that, to date, smoking is 
allowed on health premises in the U.K. In the U.S.A., 
a number of hospitals have imposed total smoking 
bans (l-3). There is overwhelming evidence of serious 
smoking-related diseases that inflict tobacco and 
passive smokers. These diseases and the premature 
deaths that they cause are preventable if only the 
afflicted did not smoke or were not exposed to 
tobacco smoke. Smoking kills 12 people every hour 
(nearly 300 people each day) in the U.K., at a cost 
to hospitals of 5437 m each year (4). If a jumbo 
jet carrying 300 passengers and crew were to crash, 
losing all these lives everyday of the year, there would 
be an ardent attempt to find out the causes of the 
accidents and stop them happening, in order to save 
lives. In spite of the number of lives being lost daily 
due to smoking-related diseases, serious and decisive 
efforts are not being made by health authorities to 
avert the carnage caused by smoking tobacco. 
The NHS Health Authorities, NHS Trusts and 
private health companies have moral and statutory 
responsibilities to provide health care and health 
promotion. Therefore, Health Authorities, Trusts 
and others ought to ban smoking on all their pre- 
mises to help this cause. Smoking bans should be 
imposed in all hospitals in the U.K. In some hospi- 
tals, ‘No Smoking’ signs and notices are clearly 
marked or displayed but are ignored by some 
smokers: staff, patients and visitors alike. Besides 
hospitals, smoking should be banned on all premises 
of general practice surgeries, health centres and day 
hospitals. Indeed, Health Authority and NHS Trust 
offices should also be no-smoking premises. 
A considerable number of psychiatric patients 
are smokers. Hence psychiatric units face immense 
problems banning smoking on such premises, as 
some of these patients, by the nature of their illnesses, 
lack insight and may be unto-operative. However, 
this should not prevent the ban from being imposed, 
even on these premises. 
There are hospitals which claim to be non-smoking 
but are not rigorous enough to keep them non- 
smoking. Currently on some health premises, where 
smoking is permitted, it is limited to certain well- 
defined areas (5). Tobacco smoke can drift from 
designated smoking areas to areas where unintended. 
Providing smoking places may be an indirect or a 
tacit message to smokers that smoking is allowed, 
maintained, or even endorsed on the premises. 
Accordingly, designated smoking areas should not be 
